The cells of a tumour carry a number of neomutations that are not homogeneously represented throughout the tumour mass. In the context of a therapy based on T-cell vaccination, this tumour polyclonality can affect the efficacy of the treatment, especially if the tumour contains cells that do not carry the mutations that induce the targeted neoantigens. Using Next Generation Sequencing, we aim to follow the frequency of these mutations in the tumour following therapeutic treatment with a lentiviral vector encoding an immunogenic protein against a panel of neoantigens.
Related team publications: